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1. Introduction 
Heart failure is supposed to be one of the most important causes of morbidity and mortality 
in the developed countries (McMurray JJ, 2000) (Cowie MR, 2000). It is not a disease by itself 
but it is a consequent condition of a number of co-existing factors including arterial 
hypertension, coronary artery heart disease and myocardiopathies. The quality of life of the 
patient is affected in heart failure more than in other diseases (Stewart AL, 1989) and the 
cost for the care providing system is estimated to be 22 billion $ each year in the United 
States (American Heart Association, 2000). Thus, investigating into heart failure causal 
factors and into management possibilities is of high importance in order to provide the 
essential help to the patients. It should be marked that the most important causal factor of 
heart failure is ischemic heart disease, thus we are dealing with heart failure developed after 
an ischemic episode if not mentioned else. 
The currently used drugs can manage effectively the main symptoms of heart failure and 
may control the symptoms of this condition. Nevertheless, judging by the numbers of 
morbidity and especially mortality, which remain high, we can assume that new research 
fields have to be developed in order to provide new effective therapies for heart failure. 
The progress in the technology and in biologic science allows the development of new 
optimized and individualized drugs with the aid of pharmacogenomics. Moreover, novel 
effective therapies emerge from the use of gene therapy and stem cell transplantation in the 
therapeutic strategies against heart failure after an ischemic episode. 
2. Currently available therapy for heart failure 
The main strategy for the currently available therapies used in the management of heart 
failure is to: a) reduce the preload, b) reduce the after load and c) improve the myocardial 
contraction. 
Depending on the New York Heart Association (NYHA) classification for heart failure there 
are four categories based upon the patient’s quality of life due to the symptoms. In NYHA 
Stage I the patient faces no symptoms when performing normal everyday work. In NYHA 
Stage II the patient has mild symptoms in everyday life, which are relieved at rest. In NYHA 
Stage III the patient has moderate symptoms that may affect the physical activity, which are 
only relieved at rest. Finally, in NYHA Stage IV the patients faces severe symptoms which 
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are present even at rest. Table 1 and Fig.1 demonstrate the main pharmaceutical categories 
used taking into consideration the NYHA Stage. 
 
NYHA Stage Stage I Stage II Stage III Stage IV 
Symptoms None Mild Moderate Severe 
ACE inhibitors Yes Yes Yes Yes 
AT1R blockers Alternatively to ACE inhibitors, when adverse reactions present 
(cough) 
beta-blockers After ACS, 
hypertension 
Yes Yes Yes 
Diuretics Hypertension, 
edema 
Yes Yes Yes 
Aldosterone 
antagonists 
Not needed In hypokalemia Yes Yes 
Digoxin In atrial fibrosis In atrial fibrosis Yes Yes 
Table 1. Main pharmaceutical categories used depending on NYHA Stage. (NYHA: New 
York Heart Association, ACE: Angiotensin Converting Enzyme, ACS: Acute Coronary 
Syndrome) 
 
 
Fig. 1. Drugs used in the management of heart failure and their mechanism of action. 
The great and increasing number of patients suffering from heart failure after ischemic 
episodes worldwide provide with the need to improve and individualize existing therapies 
and to develop novel treatments based on the promising tools of the biology and computer 
science. 
Congestion
Renin-Angiotensin 
System increase 
Sympathetic 
System increase 
Vasoconstriction 
Afteroload 
ACE 
Tachycardia 
Inotropism
Fibrosis 
Hypertrophy
Dyspnea 
Edemas
Angiotensin II
Aldosterone
Na+, H2O retention
ACE 
β-blockers 
AT1R-blockers
Spironolactone
Diuretics 
Performance 
Decrease 
Digitalis 
Cardiac output
Heart Failure 
www.intechopen.com
 
Gene Therapy Targets and the Role of Pharmacogenomics in Heart Failure 
 
325 
3. Pharmacogenomics in heart failure 
3.1 Introduction to pharmacogenomics 
In distinction to rare mutations that cause a disease, genetic polymorphisms, which are 
frequently occurring mutations, do not cause disease. Instead, they may affect the disease 
onset and outcome, the clinical cause of a disease or even response to a drug treatment. 
Genetic polymorphisms act either through alteration of the biochemic phenotype of the gene 
products as a mask for other directly involved polymorphisms (linkage disequilibrium). 
The extensive use of drugs in various populations has shown that the efficacy and toxicity 
amongst the users may differ a lot. In the USA it is estimated that 100.000 of patients die and 
2.200.000 suffer from adverse reactions attributed to drugs. The incidence in patients in a 
hospital environment is up to 6-7% and the adverse reaction to drugs is 4th amongst death 
causes (Lazarou J, 1998). 
The adverse reactions and the pharmaceutical targets are the main investigational fields 
with the aid of genetic analysis and computer science. In many cases the efficacy of a drug 
can be attributed to gene polymorphisms that encode enzymes that metabolize the drug 
itself, drug carriers or its targets. The study of genetic diversity the adverse reaction could 
be predicted and the safety and efficacy of the drug could be improved. The most effective 
therapy could be prescribed based on the special genetic alterations that the patient carries 
(March R, 2001) (Veenstra D, 2000). In the future, each patient could have an “individualized 
drug” that would be suitable to the genetic profile. 
3.2 Discovery of new targets 
The discovery of genomic regions of interest requires the DNA of the cell, which contains all 
the essential genetic information. Therefore, we can use the following techniques: 
1. Development of a cDNA library that derives from the mRNA of the studied cellular type. 
This library contains only the expressed gene of the specific tissue. 
2. Extraction of the whole DNA from the chromosomes of the studied cells. In this case the 
derivative DNA contains both introns and exons. Thus, computational tools and biologic 
techniques, such as “western blot” are required in order to define the areas of interest. 
3.2.1 DGE profiling (Differential Gene Expression) 
DGE is a technique which is used to measure the difference of the mRNA that is the product 
of a specific gene or a number of gene between two tissues. Therefore, we can find the 
specific genes expressed in a pathologic tissue, for example an ischemic tissue, and connect 
the gene to the phenotype. Thus, we can define genes responsible for the pathogenesis of a 
certain condition. The most important types of DGE is GeneCalling (Shimkets RA, 1999) and 
SAGE (de Waard V, 1999). GeneCalling has been used in a number of studies in murine 
models involving the Atrial Natriuretic Peptide and the TGF-┚  (Shimkets RA, 1999) (Geng 
YJ, 1999). The SAGE method has been used in the identification of genes participating in 
atherogenesis in the myocardial tissue (de Waard V, 1999).  
3.2.2 Database of expressed genes 
The database of expressed genes contains information from cDNA sequences that derive 
from total mRNA of the studied tissue. Therefore, if we know a specific gene that is 
expressed, then we are aware of the proteins that are produced. Special softwares are used 
in the analyses such as PHRED and PHRAP (Ewing B, 1998). In the case of heart failure 
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genes that are involved in the coagulation and the formation of the vasculature in the 
endothelium have already been scanned. 
3.2.3 ExPg (Expression Pharmacogenomics) 
The ExPg is a tool that can be used to improve the safety and efficacy of the drugs. The most 
time consuming part of a drug development is the toxicity and efficacy tests. The ExPg 
could reduce time in the pharmaceutic development and also predict the possible adverse 
reaction of a novel drug (Gould Rothberg BE, 2001). Moreover, the ExPg could be used for 
the evaluation of known metabolic and signaling pathways of the cell.  
3.2.4 SNPs (Single Nucleotide Polymorphisms) 
The SNPs are changes of a single base that may cause alterations in the protein product and 
having an impact on the functionality of the protein. Genetic polymorphisms may be the 
reason why patients may have a different response to a certain drug therapy, because a 
polymorphism may affect the metabolism of the drug or its receptors. Therefore, a better 
knowledge of possible polymorphisms may give a better prediction of the efficacy of a 
therapy. A map including the main polymorphisms involved in heart failure, atheromatosis, 
thrombosis and dyslipidemia could be produced. 
4. Gene therapy in heart failure 
The biologic progress has provided us with new knowledge regarding the mechanisms 
involved in the restoration of the heart after an ischemic episode. The novel view of the 
disease allows the use of gene therapy in order to a) facilitate revascularization in the 
ischemic myocardium, b) protect from free radicals and oxidative stress and c) improve 
myocardial contraction. 
4.1 Introduction to gene therapy 
The techniques used in gene therapy involve the introduction of a normal allele of a gene 
either because the cell does not express the gene or because the gene is under-expressed in 
that kind of cell. Before performing gene therapy a lot of work is needed to prepare the 
induction of the new gene. More specifically the following steps are followed: 
1. Isolation of the target gene 
2. Development of a specific gene vector 
3. Specification of the target cells 
4. Definition of route of administration 
5. Identification of other potential uses of the gene 
One might wonder what the importance of gene therapy is and why it is not effective to 
produce the protein that is missing and administer it to the patient afterwards. This would be 
available in large scale production schemes by the means of genetically altered bacteria. 
Nevertheless, the infusion of the protein is not curative, because of the half-life of the growth 
factors and the factors helping in angiogenesis that are used in the case of heart failure. 
4.1.1 Isolation of the target gene 
The isolation of a gene can be achieved after the production of a cDNA library that contains 
the total unique genes expressed in a specific tissue. The DNA contained in a cDNA library 
is not genomic, therefore it contains only the encoding sequences of the DNA. 
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The procedure of the construction of a cDNA library consists of the following steps:  
1. Isolation of the total amount of mRNA that is produced in the target cells,  
2. Hybridization using a multi-T promoter,  
3. Synthesis of complementary DNA (cDNA) to the mRNA prototype using the enzyme 
reverse transcriptase,  
4. Degradation of the mRNA by the means of an alkali,  
5. Synthesis of the second DNA strand using nucleotides and the enzyme DNA 
polymerase. 
The cDNA library contains only the exons of the genes that are expressed in the specific 
tissue; therefore the cDNA can show the activity of the studied tissue. 
4.1.2 Development of a specific gene vector 
As soon as the isolation of the gene that is to be administered to the patient is achieved, an 
appropriate vector is needed in order to deliver the gene to the target cells. The methods of 
genetic engineering are utilized and the gene is induced into a special agent (usually a virus 
or a chemical substance) that is used to perform transfection of the targeted cellular 
population. Therefore, the genome of the virus is inserted in the genome of the cell together 
with the gene that was previously inserted in the viral genome. 
A number of chemical agents as well as viruses are used to deliver genes to target cells and 
these are presented in the following table (Table 2). 
 
 Advantages Disadvantages 
Plasmids Well-tolerated 
Safe (Kastrupa J, 2001) 
Transfer towards the nucleus is 
not so easy (Laham RJ, 2001) 
Adeno-virus It may transfect differentiating as 
well as stale cells 
Very good percentage of transfection
It is not inserted in the nucleus 
Possibility of reaction against 
the adeno-virus (Lehrman S, 
1999) 
Retro-virus Inserted in the genome 
Stable during transport 
It can only used in transfection 
of multiplying cells (Flugelman 
MY, 1992) 
Lenti-virus Subtype of retro-virus that may be 
inserted in stable cells 
This type of virus is quite stable 
during the procedure (Sakoda T, 
1999) 
 
AAV  
(adeno-associated-
based vector) 
Inserted in the genome 
This vector is quite stable during the 
procedure 
Stable cells can be transfected as well
Only 4,7 kb can be inserted 
Possibility of mutations (Shimpo 
M, 2002) 
Liposomes – 
Oligonucleotides  
(ODN-based) 
Very easy to use 
Selective for the endothelium 
Special alterations can improve the 
availability and reduce toxicity 
(Felgner PL, 1995) 
 
Table 2. Chemical compounds and virus used in gene therapy. 
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4.1.3 Specification of the target cells 
The target cell has to be defined carefully in order to achieve the best curative result. In the 
case of heart failure, the smooth muscle cells of the heart are targeted, because in most cases 
of heart failure ischemia has already occurred. Soon after ischemia is induced, a number of 
genes alter their expression as a result of changes that take place. Therefore, it is important 
to targeting proteins as these described in the following table (Table 3) in the specified cells 
of the myocardium. 
 
Gene Function 
Heat shock proteins Protection of cellular integrity, metabolism 
and homeostasis after serious injury 
Growth factors:  
Brain-Derived Neurotrophiv factor 
Vascular Endothelial Growth Factor 
Protection and regeneration of neural and 
vascular networks 
Modulators of apoptosis: 
Plasminogen activator inhibitor 1 
Anti-apoptotic factor 
Transcription factors: 
Liver regenerating factor – Atf3 
Regulation of augmentation, anti-apoptotic 
factor 
Cell survival promoters: 
B-cell translocation gene-2 
Growth arrest and DNA-damage inducible 
gene 45a) 
Promote cellular survival, neural protection, 
DNA protection 
Table 3. Genes altering their expression in case of ischemia of the myocardium. 
4.1.4 Definition of route of administration 
The route of administration has to be defined so as the target gene is transported to the 
target cells in order to perform the transfection of the target tissue cells. In the case of heart 
failure after ischemia, the gene can be transported to: a) the epicardium (injection), b) the 
endocardium (catheter), c) the coronary arteries (catheter), d) pericardium (injection). 
4.1.5 Identification of other potential uses of the gene 
The use of a target gene in the therapy of a certain condition such as heart failure does not 
exclude a possible use of the gene in another therapeutic strategy, where there is a similar 
pathophysiology or malfunction of the studied gene or group of genes. Therefore, the 
identification of other potential uses of the target gene is always important. 
4.2 Targets of gene therapy in heart failure 
The most important cause that leads to heart failure is the ischemia of the myocardium, thus 
the post-ischemic myocardium is going to be discussed more extensively. The heart muscle 
fails to keep up to the body needs, because of the ischemia, therefore heart failure symptoms 
present. 
Soon after the crucial period of the ischemia onset in the myocardial tissue, a large number 
of genes alter their expression, as a result to the new environment that lacks oxygen. 
Consequently, only 20 minutes after the induction of ischemia an up-regulation of the 
expression of Heat Shock Protein (HSP) genes is reported, especially HSP 27, 40, 70, 86 and 
105 kDa. These proteins mainly help the ischemic tissue to maintain its integrity and 
homeostasis (Currie RW, 1987). 
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Furthermore, an increase in the expression of growth factors is measured, especially of the 
Vascular Endothelial Growth Factor (VEGF), the Brain-Derived Growth Factor (BDNF), 
which play an important role in the continuation of the stability of the myocardial and 
neural infrastructure of the myocardium (Das DK, 1995). 
The Activating Transcription Factor (Atf-3), that is also known as a factor protecting the 
liver, plays a major role in the activation and the regulation of the growth by controlling the 
expression of genes involved in late response (such as the genes that control the synthesis of 
the DNA) (Nobori K, 2002). Moreover, the Atf-3 can stop the procedure of apoptosis that 
may have been initiated as a response to ischemia (Kwaan HC, 2000).  
Finally, other genes that promote cellular survival are the Btg2 (B-cell translocation gene 2) 
and the Gadd45a (Growth arrest and DNA damage-inducible gene 45 alpha), which can also 
promote the stability of the genome and its resistance in stress conditions (Hollander MC, 
1999). 
4.2.1 Angiogenesis and revascularization in the myocardium 
VEGF (Vascular Endothelial Growth factor) 
The VEGF is an angiogenetic glucoprotein that binds to the heparin and plays a major role 
in the development of new vasculature in the ischemic myocardium (Symes JF, 2001). A 
large number of studies have investigated into the procedure of revascularization and the 
regeneration of the vascular infrastructure of the myocardium that takes place soon after the 
onset of the ischemia, and it is known that the VEGF is facilitated by a transcriptional factor 
that is promoted by hypoxia (hypoxia-inducible factor-1). Six different structural genes of 
the VEGF have already been found, but their efficacy in angiogenesis is comparable. The 
VEGF gene was the first gene to be used in experiments of gene therapy for heart failure. 
Clinical trials has shown so far that the transport of the gene in the target cell is possible by 
the means of plasmid DNA through an direct injection in the ischemic myocardium 
(Losordo DW, 1998) (or with the aid of mini-thoracotomy) (Fortuin Jr FD, 2003). In other 
studies an adeno-virus was used in order to achieve tranfection of the target cellular 
population after the injection of the gene-adeno-viral agent (Rosengart TK, 1999). 
All the studies performed in order to evaluate the use of VEGF gene in gene therapy have 
demonstrated an increase in the level of VEGF in the myocardium without substantial side-
effects that were initially supposed to emerge (such as hemangiomas or reticulopathy) 
(Symes JF, 1999) (Vale PR, 2000). Moreover, the effect of the therapy on the symptoms of 
heart failure was remarkable as angina was significantly reduced and the nitrate-free 
periods were longer (Vale PR, 2001). 
FGF (Fibroblast Growth Factor) 
Apart from the VEGF, the activation of angiogenesis can also be initiated by the Fibroblast 
Growth Factor. Clinical trials so far demonstrate that the administration of FGF-2 gene into 
the coronary artery vasculature can be well tolerated except for episodic hypotension that 
may be present for 1 up to 3 days (Fortuin Jr FD, 2003) (Simons M, 2002). In the patients that 
received the Fibroblast Growth Factor gene, 6 months after the therapy, their score in stress 
test was improved, the angina symptoms were significantly reduced, the ischemic part of 
the heart was smaller and the wall of the myocardium was thickened (Unger EF, 2000). 
The transport of the FGF gene can be achieved using an adeno-virus. The administration can 
be done through intra-coronary artery injection (Grines CL, 2002) (Grines CL, 2003). The 
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effect of the therapy on heart failure was remarkable as angina was significantly reduced 
and the nitrate-free periods were longer than before gene therapy. 
4.2.2 Protection from reperfusion injury 
The revascularization after the episode of ischemia is crucial for the myocardium. However, 
the formation of new vasculature towards the right direction is very important, otherwise 
further ischemia may develop either because of oxidative stress products or because of clot 
formation. Possible genes which are involved in the reduction of free radicals and lower the 
oxidative stress impact have already been discovered and investigated. The Superoxide 
Dismutase  gene (SOD) and the Heme Oxygenase-1 gene (HO-1) have been used in trials 
involving animal models. Nevertheless, there are no clinical trials in humans showing the 
possibility of using these target genes for avoiding reperfusion gene in post-ischemic 
myocardium.  
SOD (Superoxide Dismutase) 
It is known that the administration of the superoxide dismutase gene in rabbits soon after 
ischemia of the myocardium can reduce the development of stunning myocardium (Li Q, 
1998). The target gene of SOD, which was acquired from a cDNA library, was inserted in the 
genome of an adenovirus (Ad5/CMV/Ec-SOD) and was injected through a catheter. This 
special vector was selected, because of its selectivity to extracellular binding positions of the 
liver (Karlsson K, 1998), where the gene can be securely “stored” in order to act only when it 
is needed, without causing inflammation to the myocardium. As a result the 
revascularization of the myocardial tissue was improved, without any loss in the 
functionality of the tissue. 
HO-1 (Heme Oxygenase 1) 
The Heme Oxygenase gene 1 (HO-1) has been investigated as a potential target for gene 
therapy in experimental murine models, where reperfusion injury was present due to 
revascularization after an ischemic episode (Melo LG, 2002). A human gene was inserted in 
an adeno-viral vector and then was injected on the epicardium on the wall of the left 
ventricle (Platt JL, 1998). The transportation of the gene resulted in the reduction by 75% of 
the ischemic myocardium and in a reduction of pro-inflammatory and pro-apoptotic factors. 
When planning gene therapy in order to eliminate the oxidative stress it is essential to take 
into consideration the fact that in patients with an ischemic episode there is an increased 
probability of recurrent episodes of ischemia of the myocardium. Therefore, the gene that is 
to be used should be highly expressed in ischemic periods in order to be more effective. The 
HO-1 gene therapy does not seem to have lasting effect on the myocardial tissue, while the 
administration together with the SOD gene may lead to adverse reactions (mitochondrial 
function disruption, CO overproduction) (Tang YL, 2004). 
A special type of vectors called “vigilant vectors” was developed so as to be activated only 
in an ischemic environment (Phillips MI, 2002). The trials were performed in a murine 
model, where a vigilant plasmid containing the HO-1 gene was administrated after an acute 
ischemic episode. This experiment demonstrated less fibrotic regions in the newly 
developed vasculature, an increased expression of the HO-1 gene and improved myocardial 
contraction (Tang YL, 2004). 
Parstatin: a cryptic peptide involved in cardioprotection 
Thrombin activates protease-activated receptor 1 by proteolytic cleavage of the N-terminus. 
Although much research has focused on the activated receptor, little is known about the 41-
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amino acid N-terminal peptide (parstatin). It has been shown that parstatin would protect 
the heart against ischaemia-reperfusion injury (Routhu KV, 2010). 
A single treatment of parstatin administered prior to ischaemia may cause immediate 
cardioprotection by recruiting the Gi-protein activation pathway including p38 MAPK, 
ERK1/2, NOS, and K(ATP) channels. Parstatin acts on both the cardiomyocytes and the 
coronary circulation to induce cardioprotection. This suggests a potential therapeutic role of 
parstatin in the treatment of cardiac injury resulting from ischaemia and reperfusion 
(Strande JL, 2009). 
4.2.3 Improvement of myocardial contraction 
The role of Ca++ and phospholamban 
The intracellular bank of Ca++ in the ischemic myocardium that fails to keep up with the 
heart needs has been another target in gene therapy studies and experiments. It is known 
that the activity of the SERCA2a channel (Sarcoplasmic Reticulum Ca++ adenosine 
trophosphatase 2a channel) is reduced, resulting in decreased myocardial contraction. In 
murine models the gene of SERCA2a channel was inserted in an adeno-viral vector 
(Ad.SERCA2a) and was administered through an injection on the aorta, leading to improved 
myocardial contraction (Miyamoto MI, 2000) (del Monte F, 2001). 
The signaling with the Ca++ levels in myocardial cells also depends on the activity of an 
calcium-binding protein (called S100A1) that shares a positive inotrope action and is found 
to be at low levels in the ischemic tissue (Remppis A, 1996) (Most P, 2004). However, trials 
have shown that the administration of the respective gene can improve the myocardial 
contraction, may increase the levels of Ca++ and facilitate the activity of the SERCA2a 
channel. Thus, the use of this gene may be effective. 
The antagonism of the activity of phospholamban by the means of gene techniques has been 
investigated as well. Phospholamban has an action against SERCA2a channel; therefore its 
blockade can be beneficial for the myocardial tissue. A number of trials both in murine 
models and in humans have been accomplished (Ziolo MT, 2005) (del Monte F, 2002). An 
adenoviral vector was used in the trials. The results demonstrated improved contraction as 
the levels of phospholamban decreased 48 h after the administration of the vector. 
The β-ARs (β-adrenergic receptors) 
The most important actions of the beta-adrenergic receptor are the regulation of the cardiac 
rhythm and the myocardial contraction as a response to catecholamines. The myocardial ┚-
ARs are equally distributed in the atria and the ventricles (Ahlquist RP, 1948) (Brodde OE, 
1993). There are subtypes ┚1, ┚2, ┚3 and the ratio is ┚1AR:┚2AR=4:1. 
The ┚-ARs belong to the family of the G protein-coupled receptors (GPCRs), also known as 
seven-transmembrane domain receptors 7TM. Once a catecholamine is recognized, the 
receptor shifts conformation and, thus, mechanically activates the G protein, which detaches 
from the receptor. The receptor can now either activate another G protein or switch back to 
its inactive state. The resulting G┙ and G┚┛ subunits become active. The G┙ activates adenyl 
cyclase towards the formation of cAMP, that controls the ion channels and has a positive 
action on myocardial contraction (Dohlman HG, 1991) (Hartzell HC, 1988). 
The receptor is not active eternally as it is de-activated by the means of GPCR kinase (GRK), 
which are serine/threonine kinases. These are very selective molecules that bind and 
phosphorylate only previously activated receptors. The myocardial sup-types are GRK1 and 
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GRK2 also named as ┚ARK1 and ┚ARK2 respectively (Hausdorff WP, 1990) (Benovic JL, 
1989). 
It is known that in heart failure the density and the sensitivity of the ┚-adrenergic receptors 
are reduced. Moreover, the levels of the ┚ARK1 are increased which suggests a crucial role 
of the ┚ARK1 in the de-activation of the ┚-receptor. 
When the myocardial failure commences, the ┚-adrenergic agonists (epinephrine or nor-
epinephrine ) can be effectively used as they can increase the preload. Nevertheless, in the 
chronic condition of heart failure the myocardial load cannot benefit from the use of ┚-
agonists due to the decrease in the density and sensitivity of their receptors (Bristow MR, 
1982) (Ungerer M, 1996). 
The blockade of the ┚ARK1 by the means of gene therapy could be effective as in this case 
the de-activating role of the ┚ARK1 would be stopped, thus permitting the ┚-agonists to 
remain effective even in chronic administration. 
Another view of the matter shows the need to discover the role of ┚-arrestin. The muscles 
that act under the continuous action of the sympathetic system, ┚1-adrenergic receptors 
mediate a ┚-arrestin activation of the EGFR, thus initiating cardioprotective pathways that 
compensate the toxic action of increased catecholes (Noma T, 2007). Therefore, it is 
suggested that there are two signaling pathways, one that is G-protein dependent and 
another one that is b-arrestin dependent. The meaning of these findings is obvious as the 
design of special drugs that selectively activate or block adrenergic action can be achieved. 
5. Stem cell transplantation in heart failure 
The potential use of stem cells for regenerative medicine and for the treatment of genetic 
disease has rarely been out of the news. Discussion has focused mainly on the use of human 
embryonic stem cells, which in culture have the capacity to generate all cell types. However, 
initial hopes for stem-cell therapy have been somewhat dampened by both technical and 
ethical problems. Recent studies have therefore created a great deal of excitement. They 
show that fully differentiated somatic cells (such as skin fibroblasts) can be reprogrammed 
to make cells similar to embryonic stem cells (Douglas R, 2008). 
Experimental studies and clinical trials have revealed that Mesenchymal Stem Cells (MSCs) 
not only differentiate into cardiomyocytes and vascular cells, but also secrete amounts of 
growth factors and cytokines which may mediate endogenous regeneration via activation of 
resident cardiac stem cells and other stem cells, as well as induce neovascularization, anti-
inflammation, anti-apoptosis, anti-remodeling and cardiac contractility in a paracrine 
manner. It has also been postulated that the anti-arrhythmic and cardiac nerve sprouting 
potential of MSCs may contribute to their beneficial effects in cardiac repair. Most molecular 
and cellular mechanisms involved in the MSC-based therapy after myocardial infarction is 
still unclear at present (Wen Z, 2010). 
6. Conclusion 
To sum up, it is clear that the careful study of human genome can lead to new innovative 
views of the pathogenesis of heart failure after an ischemic episode. Therefore, the 
clarification of the genetic mechanisms which are involved in heart failure will give a boost 
to novel genetic therapies and improvement of the existing pharmaceutical therapies. 
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